Henry Schein, Inc. (NASDAQ:HSIC) Receives Average Recommendation of “Moderate Buy” from Analysts

Shares of Henry Schein, Inc. (NASDAQ:HSIC) have been assigned a consensus recommendation of “Moderate Buy” from the fifteen analysts that are covering the company, Marketbeat reports. One analyst has rated the stock with a sell recommendation, five have issued a hold recommendation and nine have given a buy recommendation to the company. The average 12 month price target among brokerages that have covered the stock in the last year is $92.9333.

A number of equities research analysts have weighed in on HSIC shares. BTIG Research boosted their price objective on Henry Schein from $100.00 to $110.00 and gave the company a “buy” rating in a research note on Wednesday, August 19th. Wall Street Zen upgraded shares of Henry Schein from a “hold” rating to a “buy” rating in a research report on Monday, August 17th. Weiss Ratings raised shares of Henry Schein from a “hold (c+)” rating to a “buy (b-)” rating in a report on Friday, August 21st. Barrington Research set a $104.00 price target on shares of Henry Schein in a research report on Wednesday, August 5th. Finally, BMO Capital Markets began coverage on shares of Henry Schein in a research note on Wednesday, July 8th. They set a “market perform” rating and a $85.00 price target for the company.

Institutional Investors Weigh In On Henry Schein

Institutional investors and hedge funds have recently made changes to their positions in the business. California State Teachers Retirement System boosted its holdings in shares of Henry Schein by 7,452.4% in the second quarter. California State Teachers Retirement System now owns 9,364,429 shares of the company’s stock valued at $782,117,000 after acquiring an additional 9,240,437 shares in the last quarter. Ameriprise Financial Inc. increased its stake in shares of Henry Schein by 3,275.2% during the second quarter. Ameriprise Financial Inc. now owns 2,266,858 shares of the company’s stock worth $165,594,000 after acquiring an additional 2,199,695 shares during the period. Bank of Montreal Can raised its holdings in Henry Schein by 3,655.7% during the fourth quarter. Bank of Montreal Can now owns 2,144,773 shares of the company’s stock worth $162,102,000 after purchasing an additional 2,087,666 shares in the last quarter. Norges Bank purchased a new position in Henry Schein during the fourth quarter worth about $88,116,000. Finally, Southpoint Capital Advisors LP lifted its position in Henry Schein by 28.0% in the first quarter. Southpoint Capital Advisors LP now owns 3,200,000 shares of the company’s stock valued at $235,840,000 after purchasing an additional 700,000 shares during the period. 96.62% of the stock is owned by hedge funds and other institutional investors.

Henry Schein Stock Performance

Shares of HSIC stock opened at $87.97 on Thursday. The stock’s 50-day moving average is $87.75 and its two-hundred day moving average is $80.61. The firm has a market cap of $9.80 billion, a price-to-earnings ratio of 25.65, a PEG ratio of 1.70 and a beta of 0.81. Henry Schein has a 1 year low of $61.94 and a 1 year high of $92.18. The company has a debt-to-equity ratio of 0.60, a quick ratio of 0.73 and a current ratio of 1.32.

Henry Schein (NASDAQ:HSIC) last posted its earnings results on Tuesday, August 4th. The company reported $1.27 earnings per share for the quarter, beating the consensus estimate of $1.24 by $0.03. The business had revenue of $3.46 billion during the quarter, compared to the consensus estimate of $3.37 billion. Henry Schein had a return on equity of 15.97% and a net margin of 2.96%.The business’s quarterly revenue was up 6.7% on a year-over-year basis. During the same period in the previous year, the business earned $1.10 EPS. Henry Schein has set its FY 2026 guidance at 5.290-5.390 EPS. Analysts predict that Henry Schein will post 5.36 earnings per share for the current year.

About Henry Schein

Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.

In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.